Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07630506
PHASE2

Folinic Acid as a Treatment for Autism Spectrum Disorder in Children

Sponsor: KK Women's and Children's Hospital

View on ClinicalTrials.gov

Summary

Autism spectrum disorder (ASD) is a neurodevelopmental condition that affects communication, behavior, and social interaction in children. Current treatments are limited and mainly focus on managing symptoms. This study aims to evaluate whether folinic acid is safe and effective in improving symptoms of autism spectrum disorder in children. Participants will be randomly assigned to receive either folinic acid or a placebo during the double-blind treatment phase. After this phase, all participants will have the option to receive folinic acid in an open-label extension. The results of this study may help determine whether folinic acid could be a potential treatment option for children with autism spectrum disorder.

Official title: Folinic Acid as a Treatment for Autism Spectrum Disorder in Children: A Double-blind Randomised Placebo-controlled Trial With Open Label Extension (FOLIN-A Trial)

Key Details

Gender

All

Age Range

3 Years - 10 Years

Study Type

INTERVENTIONAL

Enrollment

184

Start Date

2025-05-19

Completion Date

2027-06-30

Last Updated

2026-06-05

Healthy Volunteers

No

Interventions

DRUG

Folinic Acid

Oral folinic acid administered during the double-blind randomised controlled trial (RCT) phase, followed by open-label folinic acid treatment.

DRUG

Placebo

Matching oral placebo administered during the double-blind randomised controlled trial (RCT) phase.

Locations (1)

KK Women's and Children's Hospital

Singapore, Singapore, Singapore